Research & development of new pharmaceuticals for treatment of endometriosis

We noted you are experiencing viewing problems - Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443. - Check the following talk links to see which ones work correctly: Auto Mode HTTP Progressive Download Send us your results from the above test links at [email protected] and we will contact you with further advice on troubleshooting your viewing problems. - No luck yet? More tips for troubleshooting viewing issues - Contact HST Support [email protected] - Please review our troubleshooting guide for tips and advice on resolving your viewing problems. - For additional help, please don't hesitate to contact HST support [email protected] We hope you have enjoyed this limited-length demo This is a limited length demo talk; you may login or review methods of obtaining more access. Printable Handouts Navigable Slide Index - Introduction - Disclosure - Talk outline - Current treatment for endometriosis - Pathophysiology - Proliferation - Anti-proliferation by progesterone - New progestin and SPRM - Anti-proliferation - Anti-proliferation mechanism (1) - Anti-proliferation mechanism (2) - Anti-recurrence - Summary (efficacy) - Summary (safety) - Immunology - Anti-immune escape by immunomodulator - Immunosuppression - Immune response in early endometriosis - Myeloid-derived suppressor cells (MDSCs) - T cell suppression - MDSC depletion - Molecular targets - Potential immuno-modulator - Adhesion - Anti-adhesion by herbal medicines - Common TCM formulas - Anti-endometriosis (herbal medicine) - Anti-endometriosis mechanism - Common individual herbs - Single herb & dose dependent effects - Angiogenesis - Anti-angiogenesis by green tea - Camellia sinensis - Tea polyphenols (catechins) - Biological properties - Anti-endometriosis (EGCG) - Anti-angiogenesis - Anti-angiogenesis mechanism - Prodrug of EGCG (pro-EGCG) - Efficacy of pro-EGCG - Molecular interactions - RCT of green tea for endometriosis - Summary - Thanks & contact info Topics Covered - Limitation of current treatment of endometriosis - Pathophysiology of endometriosis - Anti-proliferation of endometriosis by new progesterone - Anti-immune escape of endometriosis by immunomodulator targeting MDSCs - Anti-adhesion of endometriosis by herbal medicines and active components - Anti-angiogenesis of endometriosis by green tea and derivatives - Pharmacokinetics of biologics Links Categories: Therapeutic Areas: Talk Citation Wang, C.C.(. (2019, April 30). Research & development of new pharmaceuticals for treatment of endometriosis [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved June 11, 2026, from https://doi.org/10.69645/HPSA5071.Export Citation (RIS) Publication History - Published on April 30, 2019 Financial Disclosures - Professor Wang has a patented USPTO 9713603, licenced to Aptorum Therapeutics Ltd., and grants GRF 475012, HMRF 03141386, and ITF ITS/209/12 Research & development of new pharmaceuticals for treatment of endometriosis Published on April 30, 2019 49 min A selection of talks on Pharmaceutical Sciences Transcript Please wait while the transcript is being prepared... 0:00 Hi everybody. Thank you for your interest to my talk. My name is Wang Chi Chiu Ronald, or you can call me Ronald. I am the Professor and Division Head of the Department of O&G in The Chinese University of Hong Kong. Here's where we all know, I'm happy to have a talk in Henry Stewart Talks. The topic of my talk is "R&D of New Pharmaceuticals for Treatment of Endometriosis". From the topic, you can see that I'm going to cover the treatment of endometriosis and R&D of the new pharmaceuticals. So, I hope you like it and find it very useful. 0:41 So, first of all, I would like to disclose my collaborations, funding, patents, and licenses. So, you can see that I have several collaborations with Hiu Xu in Hong Kong, McGill University and University of Oxford and also Havard University, Columbia University, and South Carolina. The funding mainly is from Hong Kong. One of them is RGC GRF, the second is ITF Tier 3 ITS and the last one is the HMRF. So, some of the contacts have a patents already. So, you can identify the ID of the patents here. One of the technology has been licensing through the pharmaceutical company. 1:29 So, basically, the talk today will cover three areas. First of all, I will give you some background information, such as why we need the pharmaceuticals and how we are going to design the new pharmaceuticals. So we're going to talk about some physiology. In the second part, we are going to introduce four main new pharmaceuticals that includes progesterone, immunodulators, herbal medicine, and lastly I'm going to give you a summary.